ArticleJournal of lipid research2012
Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology.
Article in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 161 citations in OpenAlex.
- Review
- From Complexity to Clarity: Expanding Metabolome Coverage With Innovative Analytical Strategies.Journal of separation science · 2025Review
- Transcutaneous intravascular laser irradiation of blood affects plasma metabolites of women.Scientific reports · 2024Article
- Prenatal exposure to undernutrition is associated with a specific lipid profile predicting future brain aging.npj aging · 2024Review
- Shaping immune landscape of colorectal cancer by cholesterol metabolites.EMBO molecular medicine · 2024Article
- Targeted plasma metabolomics reveals potential biomarkers of the elderly with mild cognitive impairment in Qingdao rural area.Frontiers in aging neuroscience · 2024Article
- From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.International journal of molecular sciences · 2023Review
- Plant sterols and cholesterol metabolism are associated with five-year cognitive decline in the elderly population.iScience · 2023Article
- Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?International journal of molecular sciences · 2023Review
- Analysis of the volatile organic compounds of epidural analgesia-ameliorated metabolic disorder in pregnant women with gestational diabetes mellitus based on untargeted metabolomics.Frontiers in endocrinology · 2023Observational
- Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.International journal of molecular and cellular medicine · 2023Review
- A Comprehensive Mass Spectrometry-Based Workflow for Clinical Metabolomics Cohort Studies.Metabolites · 2022Article
- High Resolution Magic Angle Spinning Proton NMR Study of Alzheimer's Disease with Mouse Models.Metabolites · 2022Article
- Discussion on Relevance and Studies of Prescription Compatibility in Chinese Medicine.Chinese journal of integrative medicine · 2021Article
- Cholesterol metabolism and brain injury in neonatal encephalopathy.Pediatric research · 2021Review
- Application of Metabolomics to Identify Potential Biomarkers for the Early Diagnosis of Coronary Heart Disease.Frontiers in physiology · 2021Article
- Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease.Respiratory research · 2020Article
- Serum Metabolic Profiling Reveals Potential Anti-Inflammatory Effects of the Intake of Black Ginseng Extracts in Beagle Dogs.Molecules (Basel, Switzerland) · 2020Article
- High-resolution metabolomic profiling of Alzheimer's disease in plasma.Annals of clinical and translational neurology · 2020Article
- Nutritional Lipidomics in Alzheimer's Disease.Advances in experimental medicine and biology · 2020Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed unbiased analysis of steroid-related compounds to identify novel Alzheimer's disease (AD) plasma biomarkers using liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy. The analysis revealed that desmosterol was found to be decreased in AD plasma versus controls. To precisely quantify variations in desmosterol, we established an analytical method to measure desmosterol and cholesterol. Using this LC-based method, we discovered that desmosterol and the desmosterol/cholesterol ratio are significantly decreased in AD. Finally, the validation of this assay using 109 clinical samples confirmed the decrease of desmosterol in AD as well as a change in the desmosterol/cholesterol ratio in AD. Interestingly, we could also observe a difference between mild cognitive impairment and control. In addition, the decrease of desmosterol was somewhat more significant in females. Receiver operating characteristic (ROC) analysis between controls and AD, using plasma desmosterol shows a score of 0.80, indicating a good discrimination power for this marker in the two reference populations and confirms the potential usefulness of measuring plasma desmosterol levels for diagnosing AD. Further analysis showed a significant correlation of plasma desmosterol with Mini-Mental State Examination scores. Although larger sample populations will be needed to confirm this diagnostic marker sensitivity, our studies demonstrate a sensitive and accurate method of detecting plasma desmosterol concentration and suggest that plasma desmosterol could become a powerful new specific biomarker for early and easy AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.